Ahmedabad Times

Fredun Prescribed drugs has introduced a 2:1 bonus concern the place the corporate can pay two totally paid-up fairness shares of Rs 10 every for each 1 present fairness share of Rs 10 every, to the eligible shareholders and warrant holders as on the document date. The choice was made in a board assembly held on Monday, Might 25 and the bonus concern cost will probably be topic to shareholders’ approval.

By the bonus share, Fredun’s strategic intent is to reward shareholders for his or her sustained confidence and long-term dedication to the corporate’s progress imaginative and prescient. The transfer indicators administration’s confidence within the structural earnings progress and long-term scalability of the enterprise with a number of high-growth engines firmly in place, the corporate’s submitting to the exchanges mentioned.

This consists of branded generic exports to 52 international locations, home Fredun Gx formulations, an built-in pet healthcare platform (Freossi, Wagr and One Pet Cease), nutraceuticals, and cosmeceuticals (Hen N Magnificence) — the Firm is well-positioned to maintain its progress trajectory.

The inauguration of its fifth GMP-certified manufacturing facility in April 2026 supplies vital capability headroom to help the following section of scaling throughout all verticals.

This transfer not solely aligns with the corporate’s constant worth creation philosophy but in addition reinforces its dedication to delivering long-term, inclusive wealth creation for shareholders.

The smallcap pharma firm is into pharmaceutical formulation manufacturing, diversified throughout generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare merchandise.
The Board of Administrators, at its assembly held on Might 25, 2026, whereby the audited monetary outcomes for This autumn and FY26 have been authorised, has really useful the issuance of bonus shares within the ratio of two:1, i.e. In FY26, Fredun reported complete revenues of Rs 639.12 crore, with an Earnings Earlier than Curiosity, Taxes, Depreciation and Amortisation (EBITDA) of Rs 94.79 Cr together with a revenue after tax (PAT) of Rs 33.21 crore.Commenting on the event, Managing Director Fredun Medhora mentioned, “The advice of a 2:1 bonus concern displays the sturdy momentum now we have constructed and our confidence in sustaining this progress trajectory. With strong efficiency throughout income and profitability, and continued progress in diversifying into higher-value segments resembling nutraceuticals, cosmeceuticals and pet healthcare, we’re strengthening the standard and scalability of our enterprise”. This bonus is a means of sharing our progress with shareholders whereas reinforcing our dedication to constant, long-term worth creation, he added.

(Disclaimer: The suggestions, ideas, views, and opinions given by the consultants are their very own. These don’t signify the views of The Financial Occasions.)